Haemodialysis anticoagulation and adequacy
暂无分享,去创建一个
V. Perkovic | P. Kerr | A. Disney | J. Petrie | J. Agar
[1] D. Cook,et al. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. , 2004, Journal of the American Society of Nephrology : JASN.
[2] V. Hasselblad,et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. , 2004, JAMA.
[3] J. Eikelboom,et al. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. , 2004, Annals of internal medicine.
[4] K. Polkinghorne,et al. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] G. La Manna,et al. Standard Heparin versus Low-Molecular-Weight Heparin , 2002, Nephron.
[6] J. Westhuyzen,et al. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] C. Szeto,et al. Use of low-dose low molecular weight heparin in hemodialysis. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.